Estradiol - Novo Nordisk

Drug Profile

Estradiol - Novo Nordisk

Alternative Names: Estrofem; Innofem; Oral estradiol; Vagifem; Vaginal estradiol

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Turner's syndrome

Most Recent Events

  • 20 Aug 2013 Biomarkers information updated
  • 23 Aug 2010 Novo Nordisk grants Upsher-Smith Laboratories marketing exclusivity in the US for estradiol 10µg vaginal tablets
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top